RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $262
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $252 to $262.
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $252 to $262.